Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00457951 · ClinicalTrials.gov registry record · Phase 2
A Study Designed to Evaluate ODSH in Subjects With Exacerbations of COPD
A Phase 2 study, sponsored by Jazz Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 158
- Enrollment target
NCT00457951: Clinical Trial Phase 2 study, sponsored by Jazz Pharmaceuticals.
NCT00457951 is a Phase 2 study that was terminated before completion, run by Jazz Pharmaceuticals. The registered enrollment target is 158 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (19% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00457951, a Phase 2 study, was terminated before completion, sponsored by Jazz Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 158 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether ODSH, when added to conventional treatment, is more effective in treating COPD exacerbations than conventional therapy alone.
Primary Outcome
The primary outcome of the study is "Treatment Failure" as defined by Failure to discharge from hospital based on GOLD (Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease) criteria or relapse after DC from hospital.
Interventions
- DRUG ODSH
- DRUG Open-Label
- DRUG Placebo Comparator: Placebo-Control Arm 0.9% Sodium Chloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 158 participants |
| Start Date | 2007-04 |
| Est. Completion | 2009-10 |
| Phase | Phase 2 |
Why NCT00457951 stopped before completion
NCT00457951 is an interventional study that assigns participants to a tested intervention. The registered 158 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (19% higher).
The record links to 0 conditions, and to 3 interventions - of which ODSH is the first listed.
NCT00457951 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00457951 about?
NCT00457951 is a clinical study titled "A Study Designed to Evaluate ODSH in Subjects With Exacerbations of COPD". The purpose of this study is to determine whether ODSH, when added to conventional treatment, is more effective in treating COPD exacerbations than conventional therapy alone.
What is the current status of trial NCT00457951?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 158 participants. The study started on 2007-04. Estimated completion is 2009-10.
What interventions are being tested in trial NCT00457951?
The interventions under investigation include: ODSH (DRUG), Open-Label (DRUG), Placebo Comparator: Placebo-Control Arm 0.9% Sodium Chloride (DRUG).
Who is sponsoring clinical trial NCT00457951?
This trial is sponsored by Jazz Pharmaceuticals, which has 128 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00457951's enrollment target sits among peer trials
158 443rd of 2000 higher than 1,558 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04486833 · 158 participants · Phase 1
Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib
- NCT04697966 · 158 participants · NA
Mechanisms and Predictors of Change in App-Based Mindfulness Training for Adolescents
- NCT04969835 · 158 participants · Phase 1
A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours
- NCT05230732 · 158 participants · NA
Neuromodulation of Inflammation and Endothelial Function
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia